MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Free Cash flow
-$7,352K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Maturities of marketable debt se...
Proceeds from sale of common sha...
Stock-based compensation
Others
Negative Cash Flow Breakdown
Purchases of marketable debt sec...
Change in fair value of warrant ...
Foreign currency remeasurement
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net loss attributable to lineage
1,482
-4,812
851
-29,781
Net income (loss) attributable to noncontrolling interest
62
23
41
29
Issuance costs for common stock warrant liabilities
0
0
0
0
Loss on impairment of intangible asset
0
-
0
0
(gain) loss on marketable equity securities, net
0
24
-7
6
Accretion of income on marketable debt securities
99
163
34
0
Depreciation and amortization expense
187
188
186
178
Change in right-of-use assets and liabilities
62
-8
-17
47
Amortization of intangible assets
-
-
0
0
Stock-based compensation
1,601
1,172
1,098
1,199
Change in fair value of warrant liability
-9,443
-2,324
-1,265
26,557
Deferred income tax benefit
-
-
-5,280
-
Foreign currency remeasurement
749
24
548
1,721
Loss on disposal of assets
-19
-12
-
-
Accounts receivable
-19
-154
827
-130
Prepaid expenses and other current assets
-654
-434
1,031
194
Accounts payable and accrued liabilities
-341
-1,711
2,459
271
Deferred revenue
-698
-995
-518
-1,780
Net cash used in operating activities
-7,244
-8,078
-4,878
-3,616
Proceeds from the sale of marketable equity securities
-
-
0
0
Purchases of marketable debt securities
10,427
8,236
14,935
0
Maturities of marketable debt securities
14,495
5,965
0
0
Purchase of equipment
108
55
399
12
Net cash provided by investing activities
3,960
-2,326
-15,334
-12
Proceeds from employee options exercised
6
227
763
487
Proceeds from exercise of warrants
0
5,388
0
319
Common shares received and retired for employee taxes paid
0
40
1
0
Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs-At The Market
4,469
-
19,632
1,276
Proceeds from sale of common shares, net of offering costs-Direct Financing
-
-
0
0
Proceeds from sale of common shares with warrants under registered direct financing, net of offering costs-Warrants Under Registered Direct Financing
0
0
0
0
Payment of financed insurance premium
0
0
0
232
Payment of finance lease liabilities
9
14
15
16
Net cash provided by financing activities
4,466
5,561
20,379
1,834
Effect of exchange rate changes on cash, cash equivalents and restricted cash
259
-5
180
-4
Net decrease in cash, cash equivalents and restricted cash
1,441
-4,848
347
-1,798
At beginning of the period
36,476
41,324
40,977
46,354
At end of the period
37,917
-
-
-
Cash paid for interest
2
-
-
-
Property and equipment expenditures in accounts payable
105
-
-
-
Financing costs in accounts payable and accrued liabilities
15
-
-
-
Fair value of warrant liability recognized upon issuance in registered direct financing
0
-
-
-
Derivative warrant liability reclassified to equity on exercise of warrants
7,442
-
-
-
Cash and cash equivalents
37,355
-
-
-
Restricted cash included in deposits and other long-term assets (see note 13 (commitments and contingencies))
562
-
-
-
Total cash, cash equivalents, and restricted cash
37,917
36,476
41,324
40,977
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from sale of
common shares with...
$4,469K
Maturities of marketable
debt securities
$14,495K
(624.75%↑ Y/Y)
Proceeds from employee
options exercised
$6K
Net cash provided by
financing activities
$4,466K
(-5.72%↓ Y/Y)
Net cash provided by
investing activities
$3,960K
(109.63%↑ Y/Y)
Effect of exchange rate
changes on cash, cash...
$259K
(17.73%↑ Y/Y)
Canceled cashflow
$9K
Canceled cashflow
$10,535K
Net decrease in
cash, cash...
$1,441K
(140.26%↑ Y/Y)
Canceled cashflow
$7,244K
Payment of finance lease
liabilities
$9K
(-67.86%↓ Y/Y)
Stock-based compensation
$1,601K
(-34.79%↓ Y/Y)
Net loss
attributable to lineage
$1,482K
(104.28%↑ Y/Y)
Prepaid expenses and
other current assets
-$654K
(48.54%↑ Y/Y)
Depreciation and
amortization expense
$187K
(-44.18%↓ Y/Y)
Change in right-of-use
assets and liabilities
$62K
(170.45%↑ Y/Y)
Net income (loss)
attributable to...
$62K
(-35.42%↓ Y/Y)
Accounts receivable
-$19K
(95.01%↑ Y/Y)
Loss on disposal of
assets
-$19K
Purchases of marketable
debt securities
$10,427K
Purchase of equipment
$108K
(-2.70%↓ Y/Y)
Net cash used in
operating activities
-$7,244K
(30.51%↑ Y/Y)
Canceled cashflow
$4,086K
Change in fair value of
warrant liability
-$9,443K
(-190.49%↓ Y/Y)
Foreign currency
remeasurement
$749K
Deferred revenue
-$698K
(81.69%↑ Y/Y)
Accounts payable and
accrued liabilities
-$341K
(25.71%↑ Y/Y)
Accretion of income on
marketable debt securities
$99K
(890.00%↑ Y/Y)
Buy us a coffee
Lineage Cell Therapeutics, Inc. (LCTX)
Lineage Cell Therapeutics, Inc. (LCTX)